Loading...

Pacific Blue™ anti-mouse CD4 Antibody Pacific Blue™ anti-mouse CD4 Antibody

Pricing & Availability
Clone
RM4-5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
RM4-5_Blue_091207
C57BL/6 mouse splenocytes stained with CD4 (clone RM4-5) Pacific Blue™ (filled histogram) or rat IgG2a, κ Pacific Blue™ isotype control (open histogram).
  • RM4-5_Blue_091207
    C57BL/6 mouse splenocytes stained with CD4 (clone RM4-5) Pacific Blue™ (filled histogram) or rat IgG2a, κ Pacific Blue™ isotype control (open histogram).
Compare all formats See Pacific Blue™ spectral data
Cat # Size Price Quantity Check Availability Save
100534 25 µg DKK559
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100531 100 µg DKK1278
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes and a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a co-receptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
BALB/c mouse thymocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with Pacific Blue™ under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The CD4 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. The suggested use of this reagent is ≤1.0 µg per 106 cells in 100 µl volume. It is highly recommended that the reagent be titrated for optimal performance for each application.

* Pacific Blue™ has a maximum emission of 455 nm when it is excited at 405 nm. Prior to using Pacific Blue™ conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the fluorochrome.


Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation.

View full statement regarding label licenses
Excitation Laser
Violet Laser (405 nm)
Application Notes

The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4+ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include: blocking of ligand binding, in vivo depletion of CD4+ cells1, and immunohistochemistry of acetone-fixed frozen tissue sections2,3,11 and paraffin-embedded sections11. Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100575 and 100576).

Application References
  1. Kruisbeek AM. 1991. In Curr. Protocols Immunol. pp. 4.1.1-4.1.5. (Block, Deplete)
  2. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  3. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045.
  4. Muraille E, et al. 2003. Infect. Immun. 71:2704. (IHC)
  5. León-Ponte M, et al. 2007. Blood 109:3139. (FC)
  6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370. (FC)
  7. Matsumoto M, et al. 2007.J. Immunol.178:2499. PubMed
  8. Shigeta A, et al. 2008. Blood 112:4915. PubMed
  9. Zaborsky N, et al. 2010. J. Immunol. 184:725. PubMed
  10. Rodrigues-Manzanet R, et al. 2010. P. Natl Acad Sci USA 107:8706. PubMed
  11. Whiteland JL, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)
Product Citations
  1. Chuang H, et al. 2014. Nat Commun. 5:4602. PubMed
  2. Lee CY, et al. 2022. J Invest Dermatol. :. PubMed
  3. Edwards KJ, et al. 2022. Cancer Immunol Res. 10:1084. PubMed
  4. Schroeter CB, et al. 2022. J Neuroinflammation. 19:270. PubMed
  5. Wang YC, et al. 2023. J Exp Med. 220:. PubMed
  6. Seclì L, et al. 2023. J Immunother Cancer. 11:. PubMed
  7. Xie J, et al. 2023. Mol Ther Oncolytics. 29:61. PubMed
  8. Kwong Chung CK, et al. 2017. Immunology. 150:221. PubMed
  9. Schuster M, et al. 2017. J Immunol. 199:920. PubMed
  10. Jankovic D, et al. 2013. J Exp Med. 210:1899. PubMed
  11. Wang L, et al. 2019. Cell Rep. 29:1848. PubMed
  12. Zhang Y, et al. 2019. Cell Res. 29:609. PubMed
  13. Her Z, et al. 2015. EMBO Mol Med. 7:24. PubMed
  14. Steubing RD, et al. 2022. Brain Behav Immun Health. 24:100493. PubMed
  15. Ooi JD, et al. 2019. Nat Commun. 10:3392. PubMed
  16. Clement M, et al. 2016. PLoS Pathog. 12:e1006050. PubMed
  17. Mier-Aguilar C, et al. 2016. PLoS One. 11:e0168155. PubMed
  18. Ku M, et al. 2016. Mol Cancer Ther. 15: 1975 - 1987. PubMed
  19. Essig K et al. 2017. Immunity. 47(6):1067-1082 . PubMed
  20. Tordesillas L, et al. 2018. Nat Commun. 9:5238. PubMed
  21. Chan YH, et al. 2019. EMBO Mol Med. 11:e10092. PubMed
  22. LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed
  23. Hung PJ, et al. 2018. Mol Cell. 71:332. PubMed
  24. Ogawa C et al. 2018. Cell reports. 25(1):19-28 . PubMed
  25. Engler JB, et al. 2019. J Immunol. 203:1743. PubMed
  26. Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed
  27. Marsh S, et al. 2016. Proc Natl Acad Sci U S A. 113: 1316 - 1325. PubMed
  28. Shi LZ, et al. 2019. Cancer Immunol Res. 1.54375. PubMed
  29. An J, et al. 2022. iScience. 25:103570. PubMed
  30. Burrack K, et al. 2015. PLoS Pathog. 11: e1005191. PubMed
  31. Lu K, et al. 2015. J Leukoc Biol. 98: 301-311. PubMed
  32. Taube C, et al. 2011. PLoS One. 6:e21799. PubMed
  33. Yang L, et al. 2021. Cell Death Differ. 28:2616. PubMed
  34. Gao J et al. 2016. Cell. 167(2):397-404 . PubMed
  35. Miska J et al. 2019. Cell reports. 27(1):226-237 . PubMed
  36. Amici SA, et al. 2021. Front Immunol. 12:695947. PubMed
  37. Aldrich AL, et al. 2021. The Journal of Immunology. 206(4):751-765. PubMed
  38. Burrack K, et al. 2015. J Immunol. 194:678. PubMed
  39. Jing Y, et al. 2020. Sci Adv. 6:eaax9455. PubMed
  40. Xiong H, et al. 2021. Theranostics. 11:1594. PubMed
  41. Bankoti R, et al. 2017. Sci Rep. 10.1038/s41598-017-12171-3. PubMed
  42. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  43. Sood S, et al. 2016. J Immunol. 197: 429 - 440. PubMed
  44. Shi L, et al. 2016. Nat Commun. 7:12335. PubMed
  45. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  46. Kolev M, et al. 2020. Immunity. 52(3):513-527. PubMed
  47. Prizant H, et al. 2021. Cell Reports. 36:109523. PubMed
  48. Teo T, et al. 2015. J Virol. 89: 7955-7969. PubMed
  49. Gorman JA, et al. 2019. Front Immunol. 10:44. PubMed
  50. Wu B, et al. 2021. Immunity. 54(2):308-323.e6. PubMed
  51. Ding Y, et al. 2013. J Immunol. 191:1614. PubMed
  52. Resch TK, et al. 2018. Sci Rep. 0.722916667. PubMed
  53. O'Leary CE, et al. 2021. Curr Protoc. 1:e77. PubMed
  54. Fernández-Orth J, et al. 2020. Eur J Immunol. . PubMed
  55. Iwata A, et al. 2017. Nat Immunol. 18:563. PubMed
  56. Niven J, et al. 2019. Cell Rep. 28:21. PubMed
  57. Schuster M, et al. 2019. Front Immunol. 10:1583. PubMed
  58. Li H, et al. 2011. J Immunol. 186:230. PubMed
  59. Jee JJ, et al. 2022. Nat Commun. 13:18. PubMed
  60. Gaylo‐Moynihan A et al. 2019. Immunity. 51(2):298-309 . PubMed
  61. Sparber F, et al. 2019. Cell Host Microbe. 25:389. PubMed
  62. Webb LM, et al. 2020. J Clin Invest. 130:1683. PubMed
  63. Reguzova A, et al. 2020. Vaccines (Basel). 8:. PubMed
  64. Hebbandi Nanjundappa R, et al. 2017. Cell. 171:655. PubMed
  65. Alterauge D, et al. 2020. Cell Rep. 33:108232. PubMed
  66. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
  67. Angelou CC, et al. 2020. Frontiers in Immunology. 2.586805556. PubMed
  68. Plaza-Sirvent C, et al. 2021. Front Immunol. 12:705436. PubMed
  69. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  70. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
  71. Chuang H, et al. 2014. Nat Commun. 5:4602. PubMed
  72. Lee CY, et al. 2022. J Invest Dermatol. :. PubMed
  73. Edwards KJ, et al. 2022. Cancer Immunol Res. 10:1084. PubMed
  74. Schroeter CB, et al. 2022. J Neuroinflammation. 19:270. PubMed
  75. Wang YC, et al. 2023. J Exp Med. 220:. PubMed
  76. Seclì L, et al. 2023. J Immunother Cancer. 11:. PubMed
  77. Xie J, et al. 2023. Mol Ther Oncolytics. 29:61. PubMed
  78. Kwong Chung CK, et al. 2017. Immunology. 150:221. PubMed
  79. Schuster M, et al. 2017. J Immunol. 199:920. PubMed
  80. Jankovic D, et al. 2013. J Exp Med. 210:1899. PubMed
  81. Wang L, et al. 2019. Cell Rep. 29:1848. PubMed
  82. Zhang Y, et al. 2019. Cell Res. 29:609. PubMed
  83. Her Z, et al. 2015. EMBO Mol Med. 7:24. PubMed
  84. Steubing RD, et al. 2022. Brain Behav Immun Health. 24:100493. PubMed
  85. Ooi JD, et al. 2019. Nat Commun. 10:3392. PubMed
  86. Clement M, et al. 2016. PLoS Pathog. 12:e1006050. PubMed
  87. Mier-Aguilar C, et al. 2016. PLoS One. 11:e0168155. PubMed
  88. Ku M, et al. 2016. Mol Cancer Ther. 15: 1975 - 1987. PubMed
  89. Essig K et al. 2017. Immunity. 47(6):1067-1082 . PubMed
  90. Tordesillas L, et al. 2018. Nat Commun. 9:5238. PubMed
  91. Chan YH, et al. 2019. EMBO Mol Med. 11:e10092. PubMed
  92. LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed
  93. Hung PJ, et al. 2018. Mol Cell. 71:332. PubMed
  94. Ogawa C et al. 2018. Cell reports. 25(1):19-28 . PubMed
  95. Engler JB, et al. 2019. J Immunol. 203:1743. PubMed
  96. Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed
  97. Marsh S, et al. 2016. Proc Natl Acad Sci U S A. 113: 1316 - 1325. PubMed
  98. Shi LZ, et al. 2019. Cancer Immunol Res. 1.54375. PubMed
  99. An J, et al. 2022. iScience. 25:103570. PubMed
  100. Burrack K, et al. 2015. PLoS Pathog. 11: e1005191. PubMed
  101. Lu K, et al. 2015. J Leukoc Biol. 98: 301-311. PubMed
  102. Taube C, et al. 2011. PLoS One. 6:e21799. PubMed
  103. Yang L, et al. 2021. Cell Death Differ. 28:2616. PubMed
  104. Gao J et al. 2016. Cell. 167(2):397-404 . PubMed
  105. Miska J et al. 2019. Cell reports. 27(1):226-237 . PubMed
  106. Amici SA, et al. 2021. Front Immunol. 12:695947. PubMed
  107. Aldrich AL, et al. 2021. The Journal of Immunology. 206(4):751-765. PubMed
  108. Burrack K, et al. 2015. J Immunol. 194:678. PubMed
  109. Jing Y, et al. 2020. Sci Adv. 6:eaax9455. PubMed
  110. Xiong H, et al. 2021. Theranostics. 11:1594. PubMed
  111. Bankoti R, et al. 2017. Sci Rep. 10.1038/s41598-017-12171-3. PubMed
  112. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  113. Sood S, et al. 2016. J Immunol. 197: 429 - 440. PubMed
  114. Shi L, et al. 2016. Nat Commun. 7:12335. PubMed
  115. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  116. Kolev M, et al. 2020. Immunity. 52(3):513-527. PubMed
  117. Prizant H, et al. 2021. Cell Reports. 36:109523. PubMed
  118. Teo T, et al. 2015. J Virol. 89: 7955-7969. PubMed
  119. Gorman JA, et al. 2019. Front Immunol. 10:44. PubMed
  120. Wu B, et al. 2021. Immunity. 54(2):308-323.e6. PubMed
  121. Ding Y, et al. 2013. J Immunol. 191:1614. PubMed
  122. Resch TK, et al. 2018. Sci Rep. 0.722916667. PubMed
  123. O'Leary CE, et al. 2021. Curr Protoc. 1:e77. PubMed
  124. Fernández-Orth J, et al. 2020. Eur J Immunol. . PubMed
  125. Iwata A, et al. 2017. Nat Immunol. 18:563. PubMed
  126. Niven J, et al. 2019. Cell Rep. 28:21. PubMed
  127. Schuster M, et al. 2019. Front Immunol. 10:1583. PubMed
  128. Li H, et al. 2011. J Immunol. 186:230. PubMed
  129. Jee JJ, et al. 2022. Nat Commun. 13:18. PubMed
  130. Gaylo‐Moynihan A et al. 2019. Immunity. 51(2):298-309 . PubMed
  131. Sparber F, et al. 2019. Cell Host Microbe. 25:389. PubMed
  132. Webb LM, et al. 2020. J Clin Invest. 130:1683. PubMed
  133. Reguzova A, et al. 2020. Vaccines (Basel). 8:. PubMed
  134. Hebbandi Nanjundappa R, et al. 2017. Cell. 171:655. PubMed
  135. Alterauge D, et al. 2020. Cell Rep. 33:108232. PubMed
  136. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
  137. Angelou CC, et al. 2020. Frontiers in Immunology. 2.586805556. PubMed
  138. Plaza-Sirvent C, et al. 2021. Front Immunol. 12:705436. PubMed
  139. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  140. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
RRID
AB_493375 (BioLegend Cat. No. 100534)
AB_493374 (BioLegend Cat. No. 100531)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.

Other Formats

View All CD4 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD4 RM4-5 FC
Biotin anti-mouse CD4 RM4-5 FC
FITC anti-mouse CD4 RM4-5 FC
PE anti-mouse CD4 RM4-5 FC
PE/Cyanine5 anti-mouse CD4 RM4-5 FC
Purified anti-mouse CD4 RM4-5 FC,CyTOF®,IHC-F,IHC
PE/Cyanine7 anti-mouse CD4 RM4-5 FC
APC/Cyanine7 anti-mouse CD4 RM4-5 FC
Alexa Fluor® 647 anti-mouse CD4 RM4-5 FC,3D IHC,IHC-F
Alexa Fluor® 488 anti-mouse CD4 RM4-5 FC,IHC-F,3D IHC
Pacific Blue™ anti-mouse CD4 RM4-5 FC
Alexa Fluor® 700 anti-mouse CD4 RM4-5 FC
PerCP anti-mouse CD4 RM4-5 FC
PerCP/Cyanine5.5 anti-mouse CD4 RM4-5 FC
Brilliant Violet 421™ anti-mouse CD4 RM4-5 FC,ICC,IHC-F
APC/Fire™ 750 anti-mouse CD4 RM4-5 FC
Brilliant Violet 570™ anti-mouse CD4 RM4-5 FC
Brilliant Violet 605™ anti-mouse CD4 RM4-5 FC
Brilliant Violet 650™ anti-mouse CD4 RM4-5 FC
Brilliant Violet 711™ anti-mouse CD4 RM4-5 FC
Brilliant Violet 785™ anti-mouse CD4 RM4-5 FC
Brilliant Violet 510™ anti-mouse CD4 RM4-5 FC
Purified anti-mouse CD4 (Maxpar® Ready) RM4-5 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse CD4 RM4-5 FC
TotalSeq™-A0001 anti-mouse CD4 RM4-5 PG
TotalSeq™-B0001 anti-mouse CD4 RM4-5 PG
TotalSeq™-C0001 anti-mouse CD4 RM4-5 PG
Ultra-LEAF™ Purified anti-mouse CD4 RM4-5 FC,CyTOF®,Depletion,Block,IHC
Spark Violet™ 423 anti-mouse CD4 RM4-5 FC
Spark Red™ 718 anti-mouse CD4 (Flexi-Fluor™) RM4-5 FC
APC/Fire™ 810 anti-mouse CD4 RM4-5 FC
PE/Fire™ 640 anti-mouse CD4 Antibody RM4-5 FC
Brilliant Violet 750™ anti-mouse CD4 Antibody RM4-5 FC
Spark YG™ 581 anti-mouse CD4 (Flexi-Fluor™) RM4-5 FC
StarBright UltraViolet 740 anti-mouse CD4 RM4-5 FC
Go To Top Version: 3    Revision Date: 01/29/2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
RM4-5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
RM4-5_Blue_091207
C57BL/6 mouse splenocytes stained with CD4 (clone RM4-5) Pacific Blue™ (filled histogram) or rat IgG2a, κ Pacific Blue™ isotype control (open histogram).
  • RM4-5_Blue_091207
    C57BL/6 mouse splenocytes stained with CD4 (clone RM4-5) Pacific Blue™ (filled histogram) or rat IgG2a, κ Pacific Blue™ isotype control (open histogram).
Compare all formats See Pacific Blue™ spectral data
Cat # Size Price Quantity Check Availability Save
100534 25 µg DKK559
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100531 100 µg DKK1278
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes and a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a co-receptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
BALB/c mouse thymocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with Pacific Blue™ under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The CD4 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. The suggested use of this reagent is ≤1.0 µg per 106 cells in 100 µl volume. It is highly recommended that the reagent be titrated for optimal performance for each application.

* Pacific Blue™ has a maximum emission of 455 nm when it is excited at 405 nm. Prior to using Pacific Blue™ conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the fluorochrome.


Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation.

View full statement regarding label licenses
Excitation Laser
Violet Laser (405 nm)
Application Notes

The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4+ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include: blocking of ligand binding, in vivo depletion of CD4+ cells1, and immunohistochemistry of acetone-fixed frozen tissue sections2,3,11 and paraffin-embedded sections11. Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100575 and 100576).

Application References
  1. Kruisbeek AM. 1991. In Curr. Protocols Immunol. pp. 4.1.1-4.1.5. (Block, Deplete)
  2. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  3. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045.
  4. Muraille E, et al. 2003. Infect. Immun. 71:2704. (IHC)
  5. León-Ponte M, et al. 2007. Blood 109:3139. (FC)
  6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370. (FC)
  7. Matsumoto M, et al. 2007.J. Immunol.178:2499. PubMed
  8. Shigeta A, et al. 2008. Blood 112:4915. PubMed
  9. Zaborsky N, et al. 2010. J. Immunol. 184:725. PubMed
  10. Rodrigues-Manzanet R, et al. 2010. P. Natl Acad Sci USA 107:8706. PubMed
  11. Whiteland JL, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)
Product Citations
  1. Chuang H, et al. 2014. Nat Commun. 5:4602. PubMed
  2. Lee CY, et al. 2022. J Invest Dermatol. :. PubMed
  3. Edwards KJ, et al. 2022. Cancer Immunol Res. 10:1084. PubMed
  4. Schroeter CB, et al. 2022. J Neuroinflammation. 19:270. PubMed
  5. Wang YC, et al. 2023. J Exp Med. 220:. PubMed
  6. Seclì L, et al. 2023. J Immunother Cancer. 11:. PubMed
  7. Xie J, et al. 2023. Mol Ther Oncolytics. 29:61. PubMed
  8. Kwong Chung CK, et al. 2017. Immunology. 150:221. PubMed
  9. Schuster M, et al. 2017. J Immunol. 199:920. PubMed
  10. Jankovic D, et al. 2013. J Exp Med. 210:1899. PubMed
  11. Wang L, et al. 2019. Cell Rep. 29:1848. PubMed
  12. Zhang Y, et al. 2019. Cell Res. 29:609. PubMed
  13. Her Z, et al. 2015. EMBO Mol Med. 7:24. PubMed
  14. Steubing RD, et al. 2022. Brain Behav Immun Health. 24:100493. PubMed
  15. Ooi JD, et al. 2019. Nat Commun. 10:3392. PubMed
  16. Clement M, et al. 2016. PLoS Pathog. 12:e1006050. PubMed
  17. Mier-Aguilar C, et al. 2016. PLoS One. 11:e0168155. PubMed
  18. Ku M, et al. 2016. Mol Cancer Ther. 15: 1975 - 1987. PubMed
  19. Essig K et al. 2017. Immunity. 47(6):1067-1082 . PubMed
  20. Tordesillas L, et al. 2018. Nat Commun. 9:5238. PubMed
  21. Chan YH, et al. 2019. EMBO Mol Med. 11:e10092. PubMed
  22. LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed
  23. Hung PJ, et al. 2018. Mol Cell. 71:332. PubMed
  24. Ogawa C et al. 2018. Cell reports. 25(1):19-28 . PubMed
  25. Engler JB, et al. 2019. J Immunol. 203:1743. PubMed
  26. Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed
  27. Marsh S, et al. 2016. Proc Natl Acad Sci U S A. 113: 1316 - 1325. PubMed
  28. Shi LZ, et al. 2019. Cancer Immunol Res. 1.54375. PubMed
  29. An J, et al. 2022. iScience. 25:103570. PubMed
  30. Burrack K, et al. 2015. PLoS Pathog. 11: e1005191. PubMed
  31. Lu K, et al. 2015. J Leukoc Biol. 98: 301-311. PubMed
  32. Taube C, et al. 2011. PLoS One. 6:e21799. PubMed
  33. Yang L, et al. 2021. Cell Death Differ. 28:2616. PubMed
  34. Gao J et al. 2016. Cell. 167(2):397-404 . PubMed
  35. Miska J et al. 2019. Cell reports. 27(1):226-237 . PubMed
  36. Amici SA, et al. 2021. Front Immunol. 12:695947. PubMed
  37. Aldrich AL, et al. 2021. The Journal of Immunology. 206(4):751-765. PubMed
  38. Burrack K, et al. 2015. J Immunol. 194:678. PubMed
  39. Jing Y, et al. 2020. Sci Adv. 6:eaax9455. PubMed
  40. Xiong H, et al. 2021. Theranostics. 11:1594. PubMed
  41. Bankoti R, et al. 2017. Sci Rep. 10.1038/s41598-017-12171-3. PubMed
  42. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  43. Sood S, et al. 2016. J Immunol. 197: 429 - 440. PubMed
  44. Shi L, et al. 2016. Nat Commun. 7:12335. PubMed
  45. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  46. Kolev M, et al. 2020. Immunity. 52(3):513-527. PubMed
  47. Prizant H, et al. 2021. Cell Reports. 36:109523. PubMed
  48. Teo T, et al. 2015. J Virol. 89: 7955-7969. PubMed
  49. Gorman JA, et al. 2019. Front Immunol. 10:44. PubMed
  50. Wu B, et al. 2021. Immunity. 54(2):308-323.e6. PubMed
  51. Ding Y, et al. 2013. J Immunol. 191:1614. PubMed
  52. Resch TK, et al. 2018. Sci Rep. 0.722916667. PubMed
  53. O'Leary CE, et al. 2021. Curr Protoc. 1:e77. PubMed
  54. Fernández-Orth J, et al. 2020. Eur J Immunol. . PubMed
  55. Iwata A, et al. 2017. Nat Immunol. 18:563. PubMed
  56. Niven J, et al. 2019. Cell Rep. 28:21. PubMed
  57. Schuster M, et al. 2019. Front Immunol. 10:1583. PubMed
  58. Li H, et al. 2011. J Immunol. 186:230. PubMed
  59. Jee JJ, et al. 2022. Nat Commun. 13:18. PubMed
  60. Gaylo‐Moynihan A et al. 2019. Immunity. 51(2):298-309 . PubMed
  61. Sparber F, et al. 2019. Cell Host Microbe. 25:389. PubMed
  62. Webb LM, et al. 2020. J Clin Invest. 130:1683. PubMed
  63. Reguzova A, et al. 2020. Vaccines (Basel). 8:. PubMed
  64. Hebbandi Nanjundappa R, et al. 2017. Cell. 171:655. PubMed
  65. Alterauge D, et al. 2020. Cell Rep. 33:108232. PubMed
  66. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
  67. Angelou CC, et al. 2020. Frontiers in Immunology. 2.586805556. PubMed
  68. Plaza-Sirvent C, et al. 2021. Front Immunol. 12:705436. PubMed
  69. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  70. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
  71. Chuang H, et al. 2014. Nat Commun. 5:4602. PubMed
  72. Lee CY, et al. 2022. J Invest Dermatol. :. PubMed
  73. Edwards KJ, et al. 2022. Cancer Immunol Res. 10:1084. PubMed
  74. Schroeter CB, et al. 2022. J Neuroinflammation. 19:270. PubMed
  75. Wang YC, et al. 2023. J Exp Med. 220:. PubMed
  76. Seclì L, et al. 2023. J Immunother Cancer. 11:. PubMed
  77. Xie J, et al. 2023. Mol Ther Oncolytics. 29:61. PubMed
  78. Kwong Chung CK, et al. 2017. Immunology. 150:221. PubMed
  79. Schuster M, et al. 2017. J Immunol. 199:920. PubMed
  80. Jankovic D, et al. 2013. J Exp Med. 210:1899. PubMed
  81. Wang L, et al. 2019. Cell Rep. 29:1848. PubMed
  82. Zhang Y, et al. 2019. Cell Res. 29:609. PubMed
  83. Her Z, et al. 2015. EMBO Mol Med. 7:24. PubMed
  84. Steubing RD, et al. 2022. Brain Behav Immun Health. 24:100493. PubMed
  85. Ooi JD, et al. 2019. Nat Commun. 10:3392. PubMed
  86. Clement M, et al. 2016. PLoS Pathog. 12:e1006050. PubMed
  87. Mier-Aguilar C, et al. 2016. PLoS One. 11:e0168155. PubMed
  88. Ku M, et al. 2016. Mol Cancer Ther. 15: 1975 - 1987. PubMed
  89. Essig K et al. 2017. Immunity. 47(6):1067-1082 . PubMed
  90. Tordesillas L, et al. 2018. Nat Commun. 9:5238. PubMed
  91. Chan YH, et al. 2019. EMBO Mol Med. 11:e10092. PubMed
  92. LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed
  93. Hung PJ, et al. 2018. Mol Cell. 71:332. PubMed
  94. Ogawa C et al. 2018. Cell reports. 25(1):19-28 . PubMed
  95. Engler JB, et al. 2019. J Immunol. 203:1743. PubMed
  96. Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed
  97. Marsh S, et al. 2016. Proc Natl Acad Sci U S A. 113: 1316 - 1325. PubMed
  98. Shi LZ, et al. 2019. Cancer Immunol Res. 1.54375. PubMed
  99. An J, et al. 2022. iScience. 25:103570. PubMed
  100. Burrack K, et al. 2015. PLoS Pathog. 11: e1005191. PubMed
  101. Lu K, et al. 2015. J Leukoc Biol. 98: 301-311. PubMed
  102. Taube C, et al. 2011. PLoS One. 6:e21799. PubMed
  103. Yang L, et al. 2021. Cell Death Differ. 28:2616. PubMed
  104. Gao J et al. 2016. Cell. 167(2):397-404 . PubMed
  105. Miska J et al. 2019. Cell reports. 27(1):226-237 . PubMed
  106. Amici SA, et al. 2021. Front Immunol. 12:695947. PubMed
  107. Aldrich AL, et al. 2021. The Journal of Immunology. 206(4):751-765. PubMed
  108. Burrack K, et al. 2015. J Immunol. 194:678. PubMed
  109. Jing Y, et al. 2020. Sci Adv. 6:eaax9455. PubMed
  110. Xiong H, et al. 2021. Theranostics. 11:1594. PubMed
  111. Bankoti R, et al. 2017. Sci Rep. 10.1038/s41598-017-12171-3. PubMed
  112. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  113. Sood S, et al. 2016. J Immunol. 197: 429 - 440. PubMed
  114. Shi L, et al. 2016. Nat Commun. 7:12335. PubMed
  115. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  116. Kolev M, et al. 2020. Immunity. 52(3):513-527. PubMed
  117. Prizant H, et al. 2021. Cell Reports. 36:109523. PubMed
  118. Teo T, et al. 2015. J Virol. 89: 7955-7969. PubMed
  119. Gorman JA, et al. 2019. Front Immunol. 10:44. PubMed
  120. Wu B, et al. 2021. Immunity. 54(2):308-323.e6. PubMed
  121. Ding Y, et al. 2013. J Immunol. 191:1614. PubMed
  122. Resch TK, et al. 2018. Sci Rep. 0.722916667. PubMed
  123. O'Leary CE, et al. 2021. Curr Protoc. 1:e77. PubMed
  124. Fernández-Orth J, et al. 2020. Eur J Immunol. . PubMed
  125. Iwata A, et al. 2017. Nat Immunol. 18:563. PubMed
  126. Niven J, et al. 2019. Cell Rep. 28:21. PubMed
  127. Schuster M, et al. 2019. Front Immunol. 10:1583. PubMed
  128. Li H, et al. 2011. J Immunol. 186:230. PubMed
  129. Jee JJ, et al. 2022. Nat Commun. 13:18. PubMed
  130. Gaylo‐Moynihan A et al. 2019. Immunity. 51(2):298-309 . PubMed
  131. Sparber F, et al. 2019. Cell Host Microbe. 25:389. PubMed
  132. Webb LM, et al. 2020. J Clin Invest. 130:1683. PubMed
  133. Reguzova A, et al. 2020. Vaccines (Basel). 8:. PubMed
  134. Hebbandi Nanjundappa R, et al. 2017. Cell. 171:655. PubMed
  135. Alterauge D, et al. 2020. Cell Rep. 33:108232. PubMed
  136. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
  137. Angelou CC, et al. 2020. Frontiers in Immunology. 2.586805556. PubMed
  138. Plaza-Sirvent C, et al. 2021. Front Immunol. 12:705436. PubMed
  139. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  140. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
RRID
AB_493375 (BioLegend Cat. No. 100534)
AB_493374 (BioLegend Cat. No. 100531)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.

Other Formats

View All CD4 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD4 RM4-5 FC
Biotin anti-mouse CD4 RM4-5 FC
FITC anti-mouse CD4 RM4-5 FC
PE anti-mouse CD4 RM4-5 FC
PE/Cyanine5 anti-mouse CD4 RM4-5 FC
Purified anti-mouse CD4 RM4-5 FC,CyTOF®,IHC-F,IHC
PE/Cyanine7 anti-mouse CD4 RM4-5 FC
APC/Cyanine7 anti-mouse CD4 RM4-5 FC
Alexa Fluor® 647 anti-mouse CD4 RM4-5 FC,3D IHC,IHC-F
Alexa Fluor® 488 anti-mouse CD4 RM4-5 FC,IHC-F,3D IHC
Pacific Blue™ anti-mouse CD4 RM4-5 FC
Alexa Fluor® 700 anti-mouse CD4 RM4-5 FC
PerCP anti-mouse CD4 RM4-5 FC
PerCP/Cyanine5.5 anti-mouse CD4 RM4-5 FC
Brilliant Violet 421™ anti-mouse CD4 RM4-5 FC,ICC,IHC-F
APC/Fire™ 750 anti-mouse CD4 RM4-5 FC
Brilliant Violet 570™ anti-mouse CD4 RM4-5 FC
Brilliant Violet 605™ anti-mouse CD4 RM4-5 FC
Brilliant Violet 650™ anti-mouse CD4 RM4-5 FC
Brilliant Violet 711™ anti-mouse CD4 RM4-5 FC
Brilliant Violet 785™ anti-mouse CD4 RM4-5 FC
Brilliant Violet 510™ anti-mouse CD4 RM4-5 FC
Purified anti-mouse CD4 (Maxpar® Ready) RM4-5 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse CD4 RM4-5 FC
TotalSeq™-A0001 anti-mouse CD4 RM4-5 PG
TotalSeq™-B0001 anti-mouse CD4 RM4-5 PG
TotalSeq™-C0001 anti-mouse CD4 RM4-5 PG
Ultra-LEAF™ Purified anti-mouse CD4 RM4-5 FC,CyTOF®,Depletion,Block,IHC
Spark Violet™ 423 anti-mouse CD4 RM4-5 FC
Spark Red™ 718 anti-mouse CD4 (Flexi-Fluor™) RM4-5 FC
APC/Fire™ 810 anti-mouse CD4 RM4-5 FC
PE/Fire™ 640 anti-mouse CD4 Antibody RM4-5 FC
Brilliant Violet 750™ anti-mouse CD4 Antibody RM4-5 FC
Spark YG™ 581 anti-mouse CD4 (Flexi-Fluor™) RM4-5 FC
StarBright UltraViolet 740 anti-mouse CD4 RM4-5 FC
Go To Top Version: 3    Revision Date: 01/29/2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account